M&A Deal Summary |
|
|---|---|
| Date | 2022-11-07 |
| Target | Fulgent Pharma |
| Sector | Life Science |
| Buyer(s) | Fulgent |
| Deal Type | Add-on Acquisition |
| Deal Value | 100M USD |
| Advisor(s) | Procopio Cory Hargreaves & Savitch (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2011 |
| Sector | Life Science |
| Employees | 1,313 |
| Revenue | 283M USD (2024) |
Fulgent is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent was founded in 2011 and is based in El Monte, California.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 3 of 3 |
| Type: Add-on Acquisition M&A Deals | 3 of 3 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 3 of 3 |
| Year: 2022 M&A | 2 of 2 |
| Size (of disclosed) | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-04-18 |
Inform Diagnostics
Irving, Texas, United States Inform Diagnostics is a provider of anatomic pathology services primarily in the fields of gastroenterology, dermatology, hematology, breast health, and urology. The company's team of more than 90 distinguished expert subspecialists utilizes state-of-the-art pathology laboratories to serve more than 5,500 patients every day. Inform Diagnostics continuously improves diagnostic accuracy through consensus-based terminology and criteria, rigorous quality assurance, daily consensus conferences, extensive educational and training activities, and close relationships with clinical partners. Inform Diagnostics was formed in 1996 and is based in Irving, Texas. |
Buy | $170M |
